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Premalignancies After Cervical Intraepithelial Neoplasia
Grade 3: A Population-Based Cohort Study
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A B S T R A C T
Purpose
The aim of this study was to determine the risk of human papillomavirus (HPV)–related carcinomas
and premalignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3).
Knowledge of this risk is important to preventing the development and progression of other HPV-
related premalignancies and carcinomas, by considering prophylactic HPV vaccination and/or by
paying increased attention to other HPV-related carcinomas and premalignancies when CIN3 is
identiﬁed.
Methods
Women diagnosed with a CIN3 between 1990 and 2010 were identiﬁed from the Dutch nationwide
registry of histopathology and cytopathology (PALGA) and matched with a control group of women
without CIN3. Subsequently, all cases of high-risk (hr) HPV–associated high-grade lesions and
carcinomas in the anogenital region and oropharynx between 1990 and 2015 were extracted. In-
cidence rate ratios were estimated for carcinomas and premalignancies of the vulva, vagina, anus,
and oropharynx.
Results
A total of 178,036 women were identiﬁed: 89,018 with a previous diagnosis of CIN3 and 89,018
matched control subjects without a history of CIN3. Women with a history of CIN3 showed in-
creased risk of HPV-related carcinomas and premalignancies, with incidence rate ratios of 3.85 (95%
CI, 2.32 to 6.37) for anal cancer, 6.68 (95%CI, 3.64 to 12.25) for anal intraepithelial neoplasia grade 3,
4.97 (95% CI, 3.26 to 7.57) for vulvar cancer, 13.66 (93% CI, 9.69 to 19.25) for vulvar intraepithelial
neoplasia grade 3, 86.08 (95%CI, 11.98 to 618.08) for vaginal cancer, 25.65 (95%CI, 10.50 to 62.69)
for vaginal intraepithelial neoplasia grade 3, and 5.51 (95% CI, 1.22 to 24.84) for oropharyngeal
cancer. This risk remained signiﬁcantly increased, even after long-term follow-up of up to 20 years.
Conclusion
This population-based study shows a long-lasting increased risk for HPV-related carcinomas and
premalignancies of the anogenital and oropharyngeal region after a CIN3 diagnosis. Studies that
investigate methods to prevent this increased risk in this group of patients, such as intensiﬁed
screening or vaccination, are warranted.
J Clin Oncol 35:2542-2550. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Infections with a high-risk human papillomavirus
(hrHPV) are estimated to be the cause of 5.2%
of all cancers worldwide.1 HrHPV infections in
women cause cervical cancer and cervical intra-
epithelial neoplasia (CIN), as well as carcinomas
and premalignancies of the oropharynx and
anogenital region including the vulva, vagina,
and anus.
The prevalence of hrHPV in cervical cancer
is close to 100%. In vaginal cancers, the prev-
alence of hrHPV is 60% to 70%, and in vulvar
cancer it ranges from 20% to 50%. In anal
cancer, an hrHPV infection is found in 88% to
95% of all cases, and 15% to 65% of oropha-
ryngeal cancers are related to the HPV.2,3
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It has been shown that womenwith a diagnosis of CIN grade 3
(CIN3) are at increased risk of carcinomas of the anogenital and
head and neck region, probably as the result of an infection with an
hrHPV.4-8 However, none of those studies included the risk for
high-grade premalignancies after a diagnosis of CIN3.4,5,8-10 Knowledge
of this risk is important to preventing the development and
progression of other HPV-related premalignancies and carci-
nomas, by considering prophylactic HPV vaccination and/or by
paying increased attention to other HPV-related carcinomas and
premalignancies when CIN3 identiﬁed. Primary prevention of
HPV-related carcinomas and premalignancies by prophylactic
vaccination is now only available for young women. Older and
unvaccinated women are therefore still at risk for HPV-related
disease in the next decades. Treating premalignancies in a cohort
may prevent malignancies from developing, and the risk for HPV-
related carcinomas and premalignancies combined represents the
possible preventive effect of HPV vaccination in women with
a CIN3. The aim of this study was therefore to determine the risk of
HPV-related carcinomas and premalignancies in women with
a previous histologic diagnosis of CIN3.
METHODS
Women with a diagnosis of CIN3 between January 1, 1990, and December
31, 2010, were identiﬁed from the Dutch nationwide registry of histo-
pathology and cytopathology (PALGA; Houten, Netherlands). Date of
birth and ﬁrst four letters of the surname were used as a personal identiﬁer.
Women registered in the database with a benign dermal nevus, but who
were never diagnosed with CIN3 or cervical carcinoma before or after the
diagnosis of nevus, were selected from the database as a control group.
Registration of a pathology result in the database was needed to obtain
a control group from the database; a registered benign dermal nevus was
chosen because it is not related to HPVand can be diagnosed in all women.
Women with both a CIN3 and a benign nevus diagnosis were included in
the CIN3 group. Control subjects were assigned a random number and
sorted. Subsequently, from the total group of 547,924 matched women
with a nevus, random frequency matching was done by age and year of
detection (both within a range of 5 years), and population density areas;
smaller cities with , 100,000 inhabitants were considered low-density
areas, and those with . 100,000 inhabitants were considered higher-
density cities. For all identiﬁed women, histology results for carcinomas
and high-grade premalignancies of the vulva, vagina, perineum, anus, and
oropharynx between January 1, 1990, and March 1, 2015, were retrieved,
resulting in 4 to 25 years of follow-up. In addition, patient age and date of
diagnosis were retrieved.
We identiﬁed all HPV-related carcinomas and premalignancies di-
agnosed after the CIN3 or benign dermal nevus. Only results with a clear
diagnosis of malignancy were classiﬁed as cancer; when invasiveness was
uncertain in a high-grade lesion, the result was classiﬁed as a high-grade
premalignancy. Moderate (CIN2) and low-grade (CIN1) premalignancies
were not included in the high-grade group. Women were censored after
diagnosis of an HPV-related carcinoma of any site because treatmentmight
inﬂuence the subsequent risk of other carcinomas or premalignancies.
Women with an HPV-related carcinoma or premalignancy before the
CIN3 or benign dermal nevus were excluded from analysis, as well as
results indicating recurrence or metastases of disease. Differentiated vulvar
intraepithelial neoplasia (VIN) and vulvar cancer after a previous diagnosis
of lichen sclerosis, clear cell carcinomas, serous adenocarcinoma, lym-
phomas, melanomas, and basal cell carcinomas were also excluded because
these are not likely to be related to HPV.11,12
We calculated person-years at risk and the number of observed
carcinomas and premalignancies in each group, taking into account
censoring as described in the previous paragraph. Using Poisson re-
gression with an offset on the basis of the person-years, incidence rates
(IR) per 100,000 person-years were estimated for both cases and their
matched controls. Incidence rate ratios (IRR), comparing women with
a CIN3 diagnosis with the matched control group, were computed,
ﬁrst by analyzing the whole follow-up period and second by excluding
the ﬁrst year of follow-up, to account for possibly prevalent HPV-
related carcinomas and premalignancies in the cohort. HPV-related
carcinomas and premalignancies were analyzed separately and com-
bined into clusters of any HPV-related carcinoma and/or any HPV-
related premalignancy. The cluster of any HPV-related carcinoma
includes anal cancer, vulvar cancer, vaginal cancer, and oropharyngeal
cancer. The cluster of any HPV-related premalignancy includes anal
intraepithelial neoplasia grade 3 (AIN3), VIN grade 3 (VIN3), and
vaginal intraepithelial neoplasia grade 3 (VAIN3). The cluster of any
malignancy or premalignancy includes anal cancer, AIN3, vulvar
cancer, VIN3, vaginal cancer, VAIN3, and oropharyngeal cancer. In all
analyses, person-years were only considered before the ﬁrst diagnosed
carcinoma or premalignancy.
Age-adjusted IRRs for 5-year follow-up intervals were estimated for
up to 25 years of follow-up for each carcinoma and premalignancy sep-
arately and for the clustered carcinomas and premalignancies, by means of
a Poisson model with an interaction term for the group with a history of
CIN3 and follow-up period and a continuous variable for age. In addition,
IRRs were estimated for women# 29 years, 30 to 49 years, 50 to 69 years,
and $ 70 years of age for the clustered carcinomas and premalignancies.
Kaplan-Meier curves were used to visualize the risk of HPV-related car-
cinomas and premalignancies over time.
All statistical analyses were performed with SAS version 9.2 (SAS
Institute, Cary, NC). Kaplan-Meier curves were obtained with SPSS version
22.0.0.1 for Windows (SPSS, Chicago, IL).
The study was approved by the scientiﬁc committee of PALGA. The
study was exempt from institutional review board approval because data
were gathered retrospectively and analyzed anonymously.
RESULTS
We identiﬁed 178,036 women, of whom 89,018 had a histologic
diagnosis of CIN3, between 1990 and 2010, and an equal number
of women in the matched control group of women without
a history of CIN3. The median age at diagnosis was 35 years in
women with a previous diagnosis of CIN3, and 36 years in the
control group. Characteristics of the study population at inclusion
are listed in Table 1. During a median follow-up of 14 years in both
groups (range, 4 to 25 years), 1,261,804 person-years were accrued
in the group with a previous diagnosis of CIN3. After censoring,
a total of 299 HPV-related carcinomas and 634 HPV-related
premalignancies were found in the group with a previous di-
agnosis of CIN3. In the control group, 1,262,998 person-years were
accrued, with 48 HPV-related carcinomas and 50 HPV-related
premalignancies (Table 2).
The risk of developing HPV-related carcinomas and pre-
malignancies of the anus, vulva, vagina, and oropharynx is strongly
associated with a previous diagnosis of CIN3, with a signiﬁcant
increase in the group with a history of CIN3 (Fig 1). The IRRs for
anal cancer and AIN3, comparing women with a previous di-
agnosis of CIN3 with those without a previous diagnosis of CIN3,
were 3.85 (95% CI, 2.32 to 6.37) and 6.68 (95% CI, 3.64 to 12.25),
respectively. For vulvar cancer and VIN3, the IRRs were 4.97 (95%
CI, 3.26 to 7.57) and 13.66 (95% CI, 9.69 to 19.25), respectively.
Vaginal cancer and VAIN3 showed the highest IRRs, with 86.08
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(95% CI, 11.99 to 618.08) for vaginal cancer and 25.65 (95% CI,
10.50 to 62.69) for VAIN3, as the result of low IRs in the control
group. Oropharyngeal cancer showed an IRR of 5.51 (95% CI, 1.22
to 24.84). The IRR for any HPV-related carcinoma was 6.24 (95%
CI, 4.60 to 8.46), for any HPV-related premalignancy the IRR was
12.75 (95% CI, 9.56 to 17.00), and for any HPV-related carcinoma
or premalignancy the IRR was 9.68 (95% CI, 7.77 to 12.05).
Excluding the ﬁrst year after inclusion resulted in IRR estimates
that were not notably different (Table 2).
The age-adjusted IRR stratiﬁed by time interval since ﬁrst
diagnosis showed a short-term and a long-lasting increased risk of
developing HPV-related carcinomas and premalignancies in
women with a previous diagnosis of CIN3, when compared with
the control group of women without a CIN3 diagnosis. Even up to
20 years after the CIN3 diagnosis, this risk remained increased
(Table 3). The increased cumulative incidence over time is clearly
visualized in the Kaplan-Meier curves (Fig 2). For the cluster of any
HPV-related carcinoma or premalignancy, the IRR decreased over
time; however, an increased risk was still visible after long-term
follow-up (Fig 3).
IRR stratiﬁed by attained age showed that the risk of carci-
noma or premalignancies for women with a history of CIN3 might
be dependent on age. The IRR of any HPV-related premalignancy
and of any carcinoma or premalignancy was highest in women #
29 years of age, both with an IRR . 30. The IRR for women with
any HPV-related carcinoma was not available. In the group of
women between 30 and 49 years of age, the risk was lower
compared with women # 29 years of age; however, the risk was
higher compared with older age groups, with IRRs of 8.09 (95%CI,
4.81 to 13.58) for any HPV-related carcinoma, 16.68 (95% CI,
11.14 to 24.96) for any HPV-related premalignancy, and 13.62
(95% CI, 9.76 to 19.01) for any HPV-related carcinoma or pre-
malignancy (Appendix Table A1, online only).
DISCUSSION
This population-based cohort study, which included 178,036
women, showed an increased risk of premalignancies as well as
carcinomas of the anus, vulva, vagina, and oropharynx in women
with a previous diagnosis of CIN3 compared with women without
a previous diagnosis of CIN3. The increased risk was still present
up to 20 years after the CIN3 diagnosis.
Our results are consistent with published studies on HPV-
related carcinomas in womenwith a CIN diagnosis, with risk ratios
ranging from 2.2 to 4.4 for vulvar cancer, 6.7 to 18.5 for vaginal
cancer, 1.8 to 5.9 for anal cancer, and 1.2 for oral/pharyngeal
tumors.4,5,7-9 No studies have analyzed the risk of HPV-related
high-grade premalignancies. In general, high-grade premalignancies
are treated before cancer can occur. Our data on IRs of high-grade
premalignancies showed high IRRs, indicating that in the group
of women with CIN3, carcinomas may have been prevented by
early detection and treatment of high-grade premalignancies.
Our data overall showed higher IRRs compared with published
results. This might be caused by differences in our study design
compared with published studies. Some studies used expected IRs
on the basis of national averaged IRs, which may also include
carcinomas in women with a CIN3 in the control group, whereas
others used relative risks. Furthermore, the studies by Kalliala
et al4 and Gaudet et al8 included women with CIN1 and/or CIN2,
of which CIN1 is known to show a lower prevalence of hrHPV
compared with CIN2/3.13
Table 1. Characteristics of Study Population at Inclusion
Characteristic No. of Patients Percentage of Patients
Person-Years of Follow-Up
CIN3 History No CIN3 History
Age cohort, years
, 20 143 0.2 1,894 1,905
20-24 2,160 2.4 32,625 32,722
25-29 10,523 11.8 161,919 161,814
30-34 25,426 28.6 350,931 351,628
35-39 20,828 23.4 307,335 306,170
40-44 13,390 15.0 185,361 186,021
45-49 7,749 8.7 104,492 105,295
50-54 3,896 4.4 54,638 54,461
55-59 2,156 2.4 28,199 28,272
60-64 1,257 1.4 16,642 16,703
65-69 505 0.6 7,602 7,683
70-74 418 0.5 5,540 5,570
75-79 303 0.3 3,113 3,220
$ 80 264 0.3 1,511 1,535
Total 89,018 100 1,261,804 1,262,998
Calendar years of inclusion
1990-1994 20,354 22.9 458,469 457,284
1995-1999 20,785 23.3 364,119 365,151
2000-2004 19,063 21.4 239,718 239,056
2005-2010 28,816 32.4 199,498 201,507
Total 89,018 100 1,261,804 1,262,998
Abbreviation: CIN3, cervical intraepithelial neoplasia grade 3.
NOTE. The number of patients and percentages of age distribution and calendar years of inclusion are similar in both groups because of 5-year matching.
2544 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ebisch et al
Downloaded from ascopubs.org by Radboud University Nijmegen on January 14, 2019 from 131.174.248.154
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Ta
bl
e
2.
O
bs
er
ve
d
N
um
be
r
of
C
ar
ci
no
m
as
an
d
P
re
m
al
ig
na
nc
ie
s,
P
er
so
n-
Y
ea
rs
,E
st
im
at
ed
In
ci
de
nc
e
R
at
es
pe
r
10
0,
00
0
P
er
so
n-
Y
ea
rs
,a
nd
In
ci
de
nc
e
R
at
e
R
at
io
s
of
C
ar
ci
no
m
as
an
d
P
re
m
al
ig
na
nc
ie
s
of
th
e
A
nu
s,
V
ul
va
,
V
ag
in
a,
an
d
O
ro
ph
ar
yn
x
of
W
om
en
W
ith
a
H
is
to
ry
of
C
er
vi
ca
lI
nt
ra
ep
ith
el
ia
lN
eo
pl
as
ia
G
ra
de
3
C
om
pa
re
d
W
ith
W
om
en
W
ith
ou
t
a
H
is
to
ry
of
C
er
vi
ca
lI
nt
ra
ep
ith
el
ia
lN
eo
pl
as
ia
G
ra
de
C
ar
ci
no
m
a
or
P
re
m
al
ig
na
nc
y
A
ll
P
er
io
ds
E
xc
lu
di
ng
Fi
rs
t
Y
ea
r
A
ft
er
In
cl
us
io
n
O
bs
er
ve
d
N
o.
P
er
so
n-
Y
ea
rs
IR
(9
5%
C
I)
IR
R
(9
5%
C
I)
O
bs
er
ve
d
N
o.
P
er
so
n-
Y
ea
rs
IR
(9
5%
C
I)
IR
R
(9
5%
C
I)
A
na
lc
an
ce
r
C
IN
3
hi
st
or
y
73
1,
26
1,
80
4
5.
79
(4
.6
0
to
7.
28
)
3.
85
(2
.3
2
to
6.
37
)
69
1,
17
2,
92
3
5.
88
(4
.6
5
to
7.
45
)
4.
32
(2
.5
1
to
7.
44
)
N
o
C
IN
3
hi
st
or
y
19
1,
26
2,
99
8
1.
50
(0
.9
6
to
2.
36
)
16
1,
17
4,
06
6
1.
36
(0
.8
4
to
2.
22
)
A
IN
3
C
IN
3
hi
st
or
y
80
1,
26
1,
21
9
6.
34
(5
.1
0
to
7.
90
)
6.
68
(3
.6
4
to
12
.2
5)
73
1,
17
2,
34
4
6.
23
(4
.9
5
to
7.
83
)
7.
31
(3
.7
8
to
14
.1
6)
N
o
C
IN
3
hi
st
or
y
12
1,
26
2,
91
2
0.
95
(0
.5
4
to
1.
67
)
10
1,
17
3,
98
2
0.
85
(0
.4
6
to
1.
58
)
V
ul
va
r
ca
nc
er
C
IN
3
hi
st
or
y
12
9
1,
26
5,
17
6
10
.2
0
(8
.5
8
to
12
.1
2)
4.
97
(3
.2
6
to
7.
57
)
11
4
1,
17
3,
00
4
9.
72
(8
.0
9
to
11
.6
8)
4.
56
(2
.9
6
to
7.
04
)
N
o
C
IN
3
hi
st
or
y
26
1,
26
6,
52
0
2.
06
(1
.4
0
to
3.
02
)
25
1,
17
4,
06
6
2.
13
(1
.4
4
to
3.
15
)
V
IN
3 C
IN
3
hi
st
or
y
47
6
1,
25
7,
67
6
37
.8
5
(3
4.
60
to
41
.4
1)
13
.6
6
(9
.6
9
to
19
.2
5)
39
5
1,
16
8,
87
4
33
.7
9
(3
0.
62
to
37
.3
0)
13
.2
2
(9
.1
2
to
19
.1
7)
N
o
C
IN
3
hi
st
or
y
35
1,
26
2,
75
9
2.
77
(1
.9
9
to
3.
86
)
30
1,
17
3,
83
2
2.
56
(1
.7
9
to
3.
66
)
V
ag
in
al
ca
nc
er
C
IN
3
hi
st
or
y
86
1,
26
1,
80
4
6.
82
(5
.5
2
to
8.
42
)
86
.0
8
(1
1.
99
to
61
8.
08
)
63
1,
17
2,
92
3
5.
37
(4
.2
0
to
6.
88
)
63
.0
6
(8
.7
5
to
45
4.
66
)
N
o
C
IN
3
hi
st
or
y
1
1,
26
2,
99
8
0.
08
(0
.0
1
to
0.
56
)
1
1,
17
4,
06
6
0.
09
(0
.0
1
to
0.
61
)
V
A
IN
3
C
IN
3
hi
st
or
y
12
8
1,
26
0,
38
7
10
.1
6
(8
.5
4
to
12
.0
8)
25
.6
5
(1
0.
50
to
62
.6
9)
76
1,
17
1,
55
9
6.
49
(5
.1
8
to
8.
12
)
15
.2
3
(6
.1
6
to
37
.6
5)
N
o
C
IN
3
hi
st
or
y
5
1,
26
2,
98
2
0.
40
(0
.1
7
to
0.
95
)
5
1,
17
4,
05
1
0.
43
(0
.1
8
to
1.
02
)
O
ro
ph
ar
yn
ge
al
ca
nc
er
C
IN
3
hi
st
or
y
11
1,
26
1,
80
4
0.
87
(0
.4
8
to
1.
57
)
5.
51
(1
.2
2
to
24
.8
4)
11
1,
17
2,
92
3
0.
94
(0
.5
2
to
1.
70
)
11
.0
1
(1
.4
2
to
85
.2
8)
N
o
C
IN
3
hi
st
or
y
2
1,
26
2,
99
8
0.
16
(0
.0
4
to
0.
63
)
1
1,
17
4,
06
6
0.
09
(0
.0
1
to
0.
61
)
A
ny
H
P
V
-re
la
te
d
ca
rc
in
om
a*
C
IN
3
hi
st
or
y
29
9
1,
26
5,
17
6
23
.6
3
(2
1.
10
to
26
.4
7)
6.
24
(4
.6
0
to
8.
46
)
25
7
1,
17
3,
00
4
21
.9
1
(1
9.
39
to
24
.7
6)
5.
98
(4
.3
3
to
8.
26
)
N
o
C
IN
3
hi
st
or
y
48
1,
26
6,
52
0
3.
79
(2
.8
6
to
5.
03
)
43
1,
17
4,
06
6
3.
66
(2
.7
2
to
4.
94
)
A
ny
H
P
V
-re
la
te
d
pr
em
al
ig
na
nc
y†
C
IN
3
hi
st
or
y
63
4
1,
25
9,
30
6
50
.3
5
(4
6.
58
to
54
.4
2)
12
.7
5
(9
.5
6
to
17
.0
0)
50
1
1,
16
7,
26
9
42
.9
2
(3
9.
32
to
46
.8
5)
11
.7
2
(8
.5
8
to
16
.0
0)
N
o
C
IN
3
hi
st
or
y
50
1,
26
6,
19
2
3.
95
(2
.9
9
to
5.
21
)
43
1,
17
3,
74
5
3.
66
(2
.7
2
to
4.
94
)
A
ny
H
P
V
-re
la
te
d
ca
rc
in
om
a
or
pr
em
al
ig
na
nc
y‡
C
IN
3
hi
st
or
y
84
7
1,
25
9,
30
6
67
.2
6
(6
2.
88
to
71
.9
5)
9.
68
(7
.7
7
to
12
.0
5)
68
3
1,
16
7,
26
9
58
.5
1
(5
4.
29
to
63
.0
7)
8.
81
(6
.9
7
to
11
.1
3)
N
o
C
IN
3
hi
st
or
y
88
1,
26
6,
19
2
6.
95
(5
.6
4
to
8.
57
)
78
1,
17
3,
74
5
6.
65
(5
.3
2
to
8.
30
)
A
bb
re
vi
at
io
ns
:A
IN
3,
an
al
in
tr
ae
pi
th
el
ia
ln
eo
pl
as
ia
gr
ad
e
3;
C
IN
3,
ce
rv
ic
al
in
tr
ae
pi
th
el
ia
ln
eo
pl
as
ia
gr
ad
e
3;
H
P
V
,h
um
an
pa
pi
llo
m
av
iru
s;
IR
,i
nc
id
en
ce
ra
te
;I
R
R
,i
nc
id
en
ce
ra
te
ra
tio
;V
A
IN
3,
va
gi
na
li
nt
ra
ep
ith
el
ia
ln
eo
pl
as
ia
gr
ad
e
3;
V
IN
3,
vu
lv
ar
in
tr
ae
pi
th
el
ia
ln
eo
pl
as
ia
gr
ad
e
3.
*A
ny
H
P
V
-re
la
te
d
ca
rc
in
om
a
in
cl
ud
es
an
al
ca
nc
er
,
vu
lv
ar
ca
nc
er
,
va
gi
na
lc
an
ce
r,
an
d
or
op
ha
ry
ng
ea
lc
an
ce
r.
†
A
ny
H
P
V
-re
la
te
d
pr
em
al
ig
na
nc
y
in
cl
ud
es
A
IN
3,
V
IN
3,
an
d
V
A
IN
3.
A
ft
er
th
e
ﬁ
rs
t
pr
em
al
ig
na
nc
y,
w
om
en
w
er
e
ce
ns
or
ed
.
‡
A
ny
H
P
V
-re
la
te
d
ca
rc
in
om
a
or
pr
em
al
ig
na
nc
y
in
cl
ud
es
an
al
ca
nc
er
,A
IN
3,
vu
lv
ar
ca
nc
er
,V
IN
3,
va
gi
na
lc
an
ce
r,
V
A
IN
3,
an
d
or
op
ha
ry
ng
ea
lc
an
ce
r.
A
ft
er
th
e
ﬁ
rs
tc
ar
ci
no
m
a
or
pr
em
al
ig
na
nc
y,
w
om
en
w
er
e
ce
ns
or
ed
.
jco.org © 2017 by American Society of Clinical Oncology 2545
Higher Risk of HPV-Related Carcinomas/Premalignancies After CIN3
Downloaded from ascopubs.org by Radboud University Nijmegen on January 14, 2019 from 131.174.248.154
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Our results showed the highest IRRs for vaginal cancer and
VAIN3 and the lowest IRR for anal cancer, which was still 3.85
(95% CI, 2.32 to 6.37). Vaginal abnormalities are in proximity to
cervical abnormalities; this makes a vaginal coinfection, with
development of a vaginal carcinoma or premalignancy, more likely
in women with a CIN3. This risk is much lower in women with no
history of CIN3, which was shown by a low IR in the control group,
resulting in a high IRR in vaginal cancer and VAIN3 after a CIN3.
Also, in vulvar carcinomas and premalignancies, a loco-regional
effect of HPVmay explain an increased incidence of these lesions in
women diagnosed with a CIN3.Women diagnosed with a CIN3 are
commonly followed up with cervical smears or colposcopic ex-
amination. This may also result in increased detection of pre-
malignancies of the vagina and vulva, with a higher IR in women
with a CIN3 compared with women without a CIN3; this could
result in an overestimation of IRR, especially in these two pre-
malignancies. Also, not all anal, vulvar, vaginal, and oropharyngeal
carcinomas and premalignancies are related to HPV; therefore, not
all malignancies and premalignancies detected during follow-up in
this study are related to HPV. We attempted to exclude carcinomas
and premalignancies that were deﬁnitely not related to HPV.
However, in the majority of cases, HPV tests were not performed
on the histology samples; thus, some carcinomas and pre-
malignancies not caused by HPV still would have been included.
However, these carcinomas and premalignancies have been
included in both the CIN3 group and in the control group of
women without CIN3, with an expected similar number of
cases; therefore, in estimated IRRs, these numbers cancel each
other out. The overall increased IRR might also be explained by
a woman’s inability or limited ability to clear an hrHPV in-
fection. A limited ability or inability to clear hrHPV infections
did result in a persistent hrHPV infection with development of
a CIN3 lesion, but could have also resulted in other HPV-related
carcinomas and premalignancies. The long-lasting increased
risk might also be explained by increased susceptibility to new
hrHPV infections and recrudescence of disease because of an
inability to clear the infection. It is known that smoking and
immunodeﬁciency increases the risk of persistent hrHPV
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Fig 1. Estimated incidence rates of human papillomavirus (HPV)–related carcinomas and premalignancies, comparing women with and without a history of cervical
intraepithelial neoplasia grade 3 (CIN3). The ﬁrst year after diagnosis of CIN3 or benign dermal nevus was included in the incidence rate visualized in this ﬁgure. Error bars
indicate 95%CIs of estimated incidence rates. The asterisks indicate a signiﬁcant difference in incidence rates of the group with a history of CIN3 compared with the group
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infections, with an increased risk of (pre)malignant develop-
ment.14-16 Data on smoking or immune status were not reg-
istered in the PALGA database, and could therefore not be
included in our analysis. Published results, however, show no
increased risk explained by smoking.9
When looking at IRR over time, almost all IRRs showed
a steady decline of increased risk during the long-term follow-up,
with the lowest increased risk after 20 to 24 years. The Kaplan-
Meier curves of all HPV-related carcinomas and premalignancies
also conﬁrmed this long-term increased risk. The increased risk of
the cluster of any HPV-related carcinoma or premalignancy over
time showed a decrease over time with an IRR of 16.44 (95% CI,
8.68 to 31.13) in the ﬁrst year, and an IRR of 2.57 (95% CI, 1.38 to
5.18) after 20 years. This indicates that although the risk of HPV-
related carcinomas and premalignancies decreased over time, it
was still signiﬁcantly increased up to 20 years after the CIN3
diagnosis. A previous study by Gaudet et al8 also showed dropping
incidences of malignancies over time, but to the contrary, Kalliala
et al4 showed an increased standardized IR for malignancies over
time after CIN3 treatment. For clusters of all carcinomas and/or all
premalignancies, we also observed decreasing IRRs with advancing
age. These data should be interpreted with some caution because
the effect of a low incidence of malignancies in younger age groups
might also be a confounding factor.
Ideally, we want to prevent the development of HPV-related
carcinomas or high-grade premalignancies, or at least discover
premalignancies before they progress to cancer. Higher alertness
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for HPV-related lesions in women with CIN3 might therefore be
advisable. During colposcopy, it is relatively easy to look for vaginal
carcinoma and premalignancies. Current guidelines advise to
also examine the vaginal walls during colposcopic examination,
and when an abnormal smear is not explained by cervical ab-
normalities, a vaginoscopy can be considered. When VAIN is di-
agnosed, it can be treated with surgical excision, laser evaporation,
or imiquimod; however, recurrent disease is a known problem.17
Also, screening for vulvar and anal carcinoma and premalignancies
might be easily combined with cervical diagnostics. Visual in-
spection will be easy to implement, but presently data are lacking
that screening of these areas results in a lower cancer incidence.
Indeed, there are no current screening programs for VIN, AIN, or
oropharyngeal lesions, but if premalignancies are encountered,
they are treated.18,19
Because an infection with hrHPV is causal to the development
of other HPV-related carcinomas and high-grade premalignancies,
prophylactic HPV vaccination may have a preventive effect on
development of these lesions. However, the role of prophylactic
vaccination in adult women is debated. Previous vaccination trials
have shown that noninfected adults could potentially beneﬁt from
HPV vaccination.20,21 Garland et al22 showed that women un-
dergoing surgical therapy for cervical lesions after vaccination with
the bivalent vaccine may beneﬁt from vaccination, with a reduced
risk of developing subsequent CIN2 positivity. Studies in women
with a current infection with hrHPV showed varying results. Two
recent studies showed a reduced incidence of subsequent HPV-
related disease in women vaccinated with the quadrivalent HPV
vaccine after surgical treatment of CIN3 when compared with
surgically treatedwomenwho did not receive theHPV vaccination.23,24
On the contrary, a recent study by Hildesheim et al25 showed no
evidence for a vaccine effect on detectable HPV infections in
hrHPV-positive women and women undergoing treatment of
cervical premalignancy. Also, the small potential harms of vac-
cination should be taken into account, alongside the fact that
HPV infections leading to premalignancies or malignancies may
have been acquired before the HPV vaccination. It is therefore
not fully clariﬁed how clinically and cost effective prophylactic
hrHPV vaccination would be in women treated for CIN3. Ran-
domized controlled trials and cost-effectiveness studies might
answer these questions. Our study, however, showed that short-
and long-term risks of HPV-related abnormalities are strongly
increased in women diagnosed with CIN3. Patients should be
informed on an individual basis about this increased risk. The
Dutch guideline presently advises to consider hrHPV vaccination
in women diagnosed with CIN3, until more conclusive evidence
on vaccine effect after treatment of CIN3 is available.17
The introduction of prophylactic HPV vaccination is expected
to reduce the incidence of HPV-related cancers; postvaccination
surveillance studies have supported this by showing a signiﬁcant
reduction of 68% in type 16 and 18 infections in countries with
female vaccination coverage of $ 50%.26-29 However, monitoring
remains essential to identify possible waning of efﬁcacy or re-
placement of HPV type. Because vaccination programs for young
women only started in 2007, it will takemany more years before the
effects of HPV vaccination become visible in the total adult female
population.
In conclusion, this population-based data set shows further
evidence of the increased risk of HPV-related carcinomas and
premalignancies of the anogenital and oropharyngeal regions after
a diagnosis of CIN3, and gives a clear view of women at risk for
HPV-related disease. Studies that investigate methods to prevent
this increased risk in this group of patients, such as intensiﬁed
screening or vaccination, are warranted.
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Appendix
Table A1. Observed Number of Carcinomas and Premalignancies, Person-Years of Follow-Up, and Estimated Incidence Rate Ratios of Carcinomas and Pre-
malignancies of Anus, Vulva, Vagina, and Oropharynx forWomenWith a History of CIN3 ComparedWithWomenWithout a History of CIN3, Stratiﬁed by Attained Age
Carcinoma or
Premalignancy
# 29 Years 30-49 Years 50-69 Years $ 70 Years
Person-
Years (ON)
IRR
(95% CI)
Person-Years
(ON)
IRR
(95% CI)
Person-Years
(ON)
IRR
(95% CI)
Person-
Years (ON)
IRR
(95% CI)
Any HPV-related carcinoma*
CIN3 history 34,739 (4) NA 836,486 (133) 8.09 355,154 (123) 4.75 38,796 (39) 8.03
No CIN3 history 42,885 (0) 813,687 (16) (4.81 to 13.58) 370,017 (27) (3.13 to 7.20) 39,931 (5) (3.16 to 20.37)
Any HPV-related
premalignancy†
CIN3 history 34,616 (29) 35.93 833,203 (427) 16.68 353,158 (150) 7.48 38,329 (28) 9.72
No CIN3 history 42,884 (1) (4.89 to 263.72) 813,557 (25) (11.14 to 24.96) 369,847 (21) (4.74 to 11.81) 39,905 (3) (2.95 to 31.96)
Any HPV-related carcinoma
or premalignancy‡
CIN3 history 34,616 (32) 39.64 833,203 (516) 13.62 353,158 (245) 5.70 38,329 (54) 11.24
No CIN3 history 42,884 (1) (5.42 to 290.09) 813,557 (37) (9.76 to 19.01) 369,847 (45) (4.15 to 7.84) 39,905 (5) (4.50 to 28.11)
Abbreviations: CIN3, cervical intraepithelial neoplasia grade 3; HPV, human papilloma virus; IRR, incidence rate ratio; NA, not available; ON, observed number.
*Any HPV-related carcinoma includes anal, vulvar, vaginal, and oropharyngeal cancer.
†Any HPV-related premalignancy includes anal intraepithelial neoplasia grade 3, vulvar intraepithelial neoplasia grade 3, and vaginal intraepithelial neoplasia grade 3.
After the ﬁrst premalignancy, women were censored.
‡Any HPV-related carcinoma or premalignancy includes anal cancer, anal intraepithelial neoplasia grade 3, vulvar cancer, vulvar intraepithelial neoplasia grade 3, vaginal
cancer, vaginal intraepithelial neoplasia grade 3, and oropharyngeal cancer. After the ﬁrst malignancy or premalignancy, women were censored.
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